as 11-21-2024 4:00pm EST
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
Founded: | 2012 | Country: | United States |
Employees: | N/A | City: | SOUTH SAN FRANCISCO |
Market Cap: | 34.4M | IPO Year: | 2019 |
Target Price: | $9.67 | AVG Volume (30 days): | 1.1M |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.25 | EPS Growth: | N/A |
52 Week Low/High: | $0.51 - $2.14 | Next Earning Date: | 11-13-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
QNCX Breaking Stock News: Dive into QNCX Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
Argus Research
4 days ago
Argus Research
7 days ago
Business Wire
8 days ago
Argus Research
9 days ago
Business Wire
9 days ago
Business Wire
10 days ago
Simply Wall St.
a month ago
The information presented on this page, "QNCX Quince Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.